Genmab A/S (NASDAQ:GMAB) Rating Lowered to Hold at Zacks Research

Genmab A/S (NASDAQ:GMAB) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

A number of other research analysts have also issued reports on the stock. Truist Financial upped their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Wall Street Zen upgraded shares of Genmab A/S from a “hold” rating to a “buy” rating in a report on Monday, July 28th. Finally, HC Wainwright upped their target price on shares of Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average price target of $37.60.

Genmab A/S Trading Up 1.0%

Shares of NASDAQ GMAB opened at $24.06 on Tuesday. The stock has a market cap of $15.44 billion, a price-to-earnings ratio of 12.09, a PEG ratio of 6.91 and a beta of 0.95. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $27.94. The company’s 50-day moving average price is $21.87 and its 200 day moving average price is $21.00.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Orbis Allan Gray Ltd grew its holdings in shares of Genmab A/S by 38.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after purchasing an additional 2,209,659 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in shares of Genmab A/S by 152.3% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,454,378 shares of the company’s stock worth $71,367,000 after purchasing an additional 2,084,966 shares during the period. Deep Track Capital LP acquired a new position in Genmab A/S during the 4th quarter worth approximately $41,740,000. First Trust Advisors LP lifted its position in Genmab A/S by 3.5% during the 2nd quarter. First Trust Advisors LP now owns 1,770,310 shares of the company’s stock worth $36,575,000 after acquiring an additional 60,504 shares in the last quarter. Finally, Brandywine Global Investment Management LLC lifted its position in Genmab A/S by 1.6% during the 2nd quarter. Brandywine Global Investment Management LLC now owns 1,744,769 shares of the company’s stock worth $36,047,000 after acquiring an additional 27,372 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.